BREAKING NEWS
Curbing global warming saves lives, studies say Israel proposes 10-month West Bank settlement halt IAEA chief: Iran must accept nuclear proposal Ga. nurse anesthetist accused of abusing patients Drywall investigation expands into US products APNewsBreak: Chairs of NFL concussion panel resign Year after NY stampede, Black Friday gets makeover Dog with name tag 'works' drive-through window Obama offers U.S. climate cut Year after NY stampede, Black Friday gets makeover Israel proposes 10-month West Bank settlement halt Free to good home: Carrier USS John F. Kennedy Thousands comment on Monsanto's planned Idaho mine Regulators approve 'OU Spirit' wind farm plan Rockford jobless rate highest of Ill. metro areas Workers at Va lumber mill eligible for federal aid QLT to pay $20 million to settle Visudyne lawsuit In recession, `Up in the Air' touches down on time The nuts and bolts of Black Friday Computer Sciences gets $2.9B service contract
AP: Breaking | Alerts | World | US | Politics | Business | Entertainment | Life | Science | Odd | Sports | Tech
BioCryst partner seeks peramivir approval in Japan
BIRMINGHAM, Ala. (AP) - BioCryst Pharmaceuticals Inc. said Wednesday its partner Shionogi & Co. filed for approval to market BioCryst's IV flu drug peramivir in Japan.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Shionogi's filing triggers a $7 million milestone payment to BioCryst.
Peramivir is an intravenous drug intended to treat the flu in patients who are hospitalized, and too sick to take an oral treatment. The government has authorized use of peramivir as a treatment for the swine flu, but clinical testing is expected to continue until 2011.
In afternoon trading, BioCryst stock rose 79 cents, or 8.5 percent, to $10.10.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
